The aim of the present study was to investigate the factors influencing the short-term response to the initial radioiodine therapy (RT) course in patients with intermediate- and high-risk papillary ...thyroid carcinoma (PTC). A total of 182 patients with intermediate- and high-risk PTC who underwent RT in our hospital from March 2018 to October 2020 were retrospectively enrolled. The patients were divided into incomplete response (IR) and nonincomplete response (Non-IR) groups according to the response observed in clinical follow-up within 6–12 months after RT. Univariate and multivariate logistic regression analyses were used to investigate the effects of 15 observed factors on the response to RT. Receiver operating characteristic (ROC) curve analysis was used to determine the value of factors found to be significant in multivariate analyses for predicting an IR. A total of 182 patients with intermediate- and high-risk PTC were analyzed; the percentage of patients with a Non-IR was 61.54% (112/182), and the percentage of patients with an IR was 38.46% (70/182). The CD4
+
T-cell percentage (
t
= 4.757,
P
= 0.000), CD4/CD8 (
z
= − 2.632,
P
= 0.008), stimulated thyroglobulin (sTg) level (
z
= − 8.273,
P
= 0.000) and M stage (
χ
2
= 17.823,
P
= 0.000) of the two groups were significantly different. Multivariate analysis showed that only the sTg level (OR: 1.116, 95% CI 1.068–1.165,
P
< 0.001) and CD4
+
T-cell percentage (OR: 0.909, 95% CI 0.854–0.968,
P
= 0.003) were independent factors associated with the therapeutic response to RT. The cutoff sTg level and CD4
+
T-cell percentage for predicting an IR were 7.62 μg/L and 40.95%, respectively. The sTg level and CD4
+
T-cell percentage were verified to be independent predictive factors of RT response. Higher sTg levels and lower CD4
+
T-cell percentages were related to an IR in patients with intermediate- and high-risk PTC.
Purpose This two-center study aimed to explore the main prognostic factors affecting the final disease status in children and adolescents with differentiated thyroid cancer (caDTC) following total ...thyroidectomy and radioiodine therapy (RAIT). Materials and methods All caDTC patients from two centers in the period from 2004-2022 were retrospectively included. At the last follow-up, the patients’ disease status was assessed and classified as an incomplete response (IR) or as an excellent or indeterminate response (EIDR). Then, the difference in preablation stimulated thyroglobulin (ps-Tg) levels between the two groups was compared, and the threshold for predicting IR was determined using receiver operating characteristic (ROC) analysis. Moreover, univariate and multivariate analyses were conducted to identify the factors influencing the patients’ ultimate disease outcomes. Results A total of 143 patients (98 females, 45 males; median age 16 years) were recruited. After a median follow-up of 42.9 months, 80 patients (55.9%) exhibited an EIDR, whereas 63 patients (44.1%) exhibited an IR. Patients with an IR had significantly greater ps-Tg levels than did those with an EIDR (median ps-Tg 79.2 ng/mL vs. 9.3 ng/mL, p<0.001). The ROC curve showed that ps-Tg ≥20 ng/mL was the most accurate for predicting IR at the last follow-up. According to multivariate analysis, only ps-Tg, T stage and the therapeutic response to initial RAIT were significantly associated with IR. Conclusion In caDTC patients, the ps-Tg level, T stage, and response to initial RAIT are critical final outcome indicators.
Objective
We aimed to explore the predictive value of stimulated thyroglobulin (sTg) and pre-ablation antithyroglobulin (pa-TgAb) products for the effect of radioiodine therapy (RAIT) on ...TgAb-positive differentiated thyroid cancer (DTC) patients.
Methods
In this study, we enrolled 265 patients with TgAb-positive DTC who underwent RAIT after total thyroidectomy (TT). Based on the last follow-up result, the patients were divided into two groups: the excellent response (ER) group and the non-excellent response (NER) group. We analyzed the factors related to the effect of RAIT.
Results
The ER group consisted of 197 patients. The NER group consisted of 68 patients. For the univariate analysis, we found that the maximal tumor diameter, whether with extrathyroidal extension (ETE), bilateral or unilateral primary lesion, multifocality, preoperative TgAb (preop-TgAb), pa-TgAb, sTg × pa-TgAb, initial RAIT dose, N stage, and surgical extent (modified radical neck dissection or not), showed significant differences between the ER group and NER group (all
p
-values <0.05). The receiver operating characteristic (ROC) curves showed that the cutoff value was 724.25 IU/ml, 424.00 IU/ml, and 59.73 for preop-TgAb, pa-TgAb, and sTg × pa-TgAb, respectively. The multivariate logistic regression analysis results indicated that pa-TgAb, sTg × pa-TgAb, initial RAIT dose, and N stage were independent risk factors for NER (all
p
-values <0.05). For the Kaplan–Meier analysis of disease-free survival (DFS), the median DFS of the patients with sTg × pa-TgAb < 59.73 and initial RAIT dose ≤ 100 mCi was significantly longer than that of the patients with sTg × pa-TgAb ≥ 59.73 (50.27 months vs. 48.59 months,
p
= 0.041) and initial RAIT dose >100 mCi (50.50 months vs. 38.00 months,
p
= 0.030).
Conclusion
We found the sTg and pa-TgAb conducts is a good predictor of the efficacy of RAIT in TgAb-positive DTC patients. It can play a very positive and important role in optimizing treatment, improving prognosis, and reducing the burden of patients.
I treatment is one of the important methods of comprehensive postoperative treatment for patients with hyperthyroidism complicated with differentiated thyroid cancer (DTC). Early identification of ...patients with poor treatment efficacy of
I is particularly important. Current studies mainly focus on the relationship between hyperthyroidism and the occurrence and development of DTC, and there are few studies on the factors affecting the curative effect. The purpose of this study was to find the influencing factors of efficacy evaluation and provide evidence for early identification of patients with poor efficacy in DTC combined with primary hyperthyroidism patients.
This was a retrospective analysis of DTC patients with primary hyperthyroidism who received
I treatment in our department from 2012 to 2021. Follow-up intervals were 3 months within 1 year, 6 months within 1 to 2 years, and annual follow-up thereafter, the median follow-up time was 12.0 (3.0, 24.0) months. Serological examination and imaging examination were used to evaluate the efficacy. Patients were classified into an excellent response (ER) group and a non-ER group based on treatment response more than 6 months after
I treatment. Univariate analysis and multivariate logistic regression analysis were performed on the basic clinical characteristics, pathological characteristics and curative effect of the patients, in order to find independent risk factors affecting the curative effect.
Eighty-nine patients were mostly female (80.9%), the average age was 43.47±11.88 years old, and tumor size was 1.2 (0.75, 1.80) cm, 56 patients (62.9%) in the ER group. psTg odds ratio (OR): 1.325; 95% confidence interval (CI): 1.135-1.547; P<0.001, maximum tumor diameter (OR: 2.428; 95% CI: 1.392-4.235; P=0.002) and pathology-confirmed combined HT (OR: 8.669; 95% CI: 1.877-40.038; P=0.006) were independent risk factors for predicting ER.
Our findings demonstrate that most hyperthyroidism combined with DTC patients could get favorable clinical outcomes from
I treatment. The tumor diameter, pathology-confirmed diagnosis of combined HT, and psTg level can be used to identify patients who can get ER by the effect of
I in hyperthyroidism combined with DTC at an early stage.
Background131I treatment is one of the important methods of comprehensive postoperative treatment for patients with hyperthyroidism complicated with differentiated thyroid cancer (DTC). Early ...identification of patients with poor treatment efficacy of 131I is particularly important. Current studies mainly focus on the relationship between hyperthyroidism and the occurrence and development of DTC, and there are few studies on the factors affecting the curative effect. The purpose of this study was to find the influencing factors of efficacy evaluation and provide evidence for early identification of patients with poor efficacy in DTC combined with primary hyperthyroidism patients. MethodsThis was a retrospective analysis of DTC patients with primary hyperthyroidism who received 131I treatment in our department from 2012 to 2021. Follow-up intervals were 3 months within 1 year, 6 months within 1 to 2 years, and annual follow-up thereafter, the median follow-up time was 12.0 (3.0, 24.0) months. Serological examination and imaging examination were used to evaluate the efficacy. Patients were classified into an excellent response (ER) group and a non-ER group based on treatment response more than 6 months after 131I treatment. Univariate analysis and multivariate logistic regression analysis were performed on the basic clinical characteristics, pathological characteristics and curative effect of the patients, in order to find independent risk factors affecting the curative effect. ResultsEighty-nine patients were mostly female (80.9%), the average age was 43.47±11.88 years old, and tumor size was 1.2 (0.75, 1.80) cm, 56 patients (62.9%) in the ER group. psTg odds ratio (OR): 1.325; 95% confidence interval (CI): 1.135-1.547; P<0.001, maximum tumor diameter (OR: 2.428; 95% CI: 1.392-4.235; P=0.002) and pathology-confirmed combined HT (OR: 8.669; 95% CI: 1.877-40.038; P=0.006) were independent risk factors for predicting ER. ConclusionsOur findings demonstrate that most hyperthyroidism combined with DTC patients could get favorable clinical outcomes from 131I treatment. The tumor diameter, pathology-confirmed diagnosis of combined HT, and psTg level can be used to identify patients who can get ER by the effect of 131I in hyperthyroidism combined with DTC at an early stage.
Self-poling has been found in many two-dimensional epitaxial ferroelectric nanofilms originating from epitaxial growth clamping and has become a new research focus due to its potential applications ...in designing new types of ferroelectric devices. However, self-poling ferroelectrics based on internal strain gradients rather than external stimuli still do not exist. Here, we demonstrate a novel and unique design for one-dimensional structures and geometries in microscale with robust upward flexoelectric self-poling created by the application of electrospun ferroelectric fibers on a patterned substrate to introduce curving structure arises from the uneven substrate and confinement by other fibers in space. The fiber textile composed of these curving structures could resist external electric field and temperature, and can be fabricated into high performance poling-free flexible nanogenerators with outputs comparable to the poled ones. These results are conducive to providing a potential solution to the depolarization problem, to simplifying the technologies for manufacturing piezoelectric nanogenerators by avoiding the application of electric field for poling, and to providing extra freedom in controlling ferroelectric polarization and designing new types of devices.
Display omitted
•Unique design of self-poled ferroelectric fibers with curving structure.•The curving strain gradient and ferroelectric effect is molded and calculated.•The stable self-poled fibers could resist external electric field and temperature.•Nanogenerator fabricated by self-poled fibers has outputs comparable to the poled one.
